1. Naproxen as Prophylaxis against Atrial Fibrillation after Cardiac Surgery: The NAFARM Randomized Trial
- Author
-
Claudio Cirenza, Felipe Martini, Adauto Castelo Filho, João Batista Petracco, João Carlos Vieira da Costa Guaragna, Luiz Carlos Bodanese, Angelo Amato Vicenzo de Paola, Stevie Jorge Horbach, Renato D. Lopes, Rajendra H. Mehta, Nafarm Investigators, Duke Univ, Universidade Federal de São Paulo (UNIFESP), Pontificia Univ Catolica Rio Grande do Sul, and Brazilian Clin Res Inst
- Subjects
Male ,medicine.medical_specialty ,Naproxen ,Coronary artery bypass graft surgery ,Placebo ,law.invention ,Postoperative Complications ,Double-Blind Method ,Randomized controlled trial ,law ,Atrial Fibrillation ,medicine ,Humans ,Data monitoring committee ,Prospective Studies ,Prospective cohort study ,Aged ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Atrial fibrillation ,General Medicine ,Acute Kidney Injury ,Length of Stay ,Middle Aged ,medicine.disease ,Intensive care unit ,Surgery ,Cardiac surgery ,Intensive Care Units ,Anesthesia ,Early Termination of Clinical Trials ,Nonsteroidal anti-inflammatory ,Female ,business ,Brazil ,medicine.drug - Abstract
PURPOSE: We sought to assess the effect of naproxen versus placebo on prevention of atrial fibrillation after coronary artery bypass graft (CABG) surgery.METHODS: in this randomized, double-blind, placebo-controlled, single-center trial of 161 consecutive patients undergoing CABG surgery, patients received naproxen 275 mg every 12 hours or placebo at the same dosage and interval over 120 hours immediately after CABG surgery. the primary outcome was the occurrence of atrial fibrillation in the first 5 postoperative days.RESULTS: the incidence of postoperative atrial fibrillation was 15.2% (12/79) in the placebo versus 7.3% (6/82) in the naproxen group (P = .11). the duration of atrial fibrillation episodes was significantly lower in the naproxen (0.35 hours) versus placebo group (3.74 hours; P = .04). There was no difference in the overall days of hospitalization between placebo (17.23 +/- 7.39) and naproxen (18.33 +/- 9.59) groups (P = .44). Intensive care unit length of stay was 4.0 +/- 4.57 days in the placebo and 3.23 +/- 1.25 days in the naproxen group (P = .16). the trial was stopped by the data monitoring committee before reaching the initial target number of 200 patients because of an increase in renal failure in the naproxen group (7.3% vs 1.3%; P = .06).CONCLUSIONS: Postoperative use of naproxen did not reduce the incidence of atrial fibrillation but decreased its duration, in a limited sample of patients after CABG surgery. There was a significant increase in acute renal failure in patients receiving naproxen 275 mg twice daily. Our study does not support the routine use of naproxen after CABG surgery for the prevention of atrial fibrillation. (C) 2011 Elsevier Inc. All rights reserved. . the American Journal of Medicine (2011) 124, 1036-1042 Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27705 USA Universidade Federal de São Paulo, Div Invas Clin Electrophysiol, Dept Cardiol, São Paulo, Brazil Pontificia Univ Catolica Rio Grande do Sul, Div Cardiol, Porto Alegre, RS, Brazil Brazilian Clin Res Inst, São Paulo, Brazil Universidade Federal de São Paulo, Div Invas Clin Electrophysiol, Dept Cardiol, São Paulo, Brazil Web of Science
- Published
- 2011
- Full Text
- View/download PDF